Dr Montalbán Bravo meets with ecancertv at ASH 2016 to discuss the aetiology and prognostic outlook of pure erythroid leukaemia, a subset of acute leukaemia.

He discusses the cell lineage of the disease, and describes sequencing data helping to form a greater genetic and biological understanding of PEL and its treatment choices.

Dr Montalbán Bravo also spoke with ecancer about the clinical utility of guadecitabine and azacitadine plus verinostat.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.